Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | PTGIR | P43119 | 5/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13803669 | 0.88 | ACHE (0.59) | ACHENAMPTEPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL28861303 | 0.85 | ACHE (0.62) | ACHENAMPTEPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL7480840 | 0.83 | ACHE (0.52) | ACHENAMPTEPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL4677007 | 0.80 | ACHE (0.59) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL4678438 | 0.80 | ACHE (0.63) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL27748883 | 0.80 | ACHE (0.68) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL2781381 | 0.78 | MEN1 (0.68) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL14597201 | 0.78 | ACHE (0.61) | ACHEEPHX1L3MBTL3L3MBTL1HPGD | |
| SCHEMBL4283757 | 0.78 | ACHE (0.56) | ACHENAMPTEPHX1L3MBTL3L3MBTL1 | |
| SCHEMBL77520 | 0.77 | SMN1; SMN2 (0.67) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| EP-1227090-A1 | AMINE DERIVATIVES | Tadeka Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | ACHE 1062/4885PTGIR 249/4885NAMPT 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.